<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04249804</url>
  </required_header>
  <id_info>
    <org_study_id>MS-261-2019</org_study_id>
    <nct_id>NCT04249804</nct_id>
  </id_info>
  <brief_title>the Use of Magnesium Sulfate for Prevention of Postspinal Shivering</brief_title>
  <official_title>Intravenous Infusion Versus Intrathecal Injection of Magnesium Sulfate for Prevention of Postspinal Shivering During Lower Limb Fracture Surgery. A Randomized Comparative Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cairo University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Cairo University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Shivering is an unpleasant experience after spinal anesthesia. Shivering is defined as an
      involuntary, repetitive activity of skeletal muscles. The mechanisms of shivering in patients
      undergoing surgery are mainly intraoperative heat loss, increased sympathetic tone, pain, and
      systemic release of pyrogens. Spinal anesthesia significantly impairs the thermoregulation
      system by inhibiting tonic vasoconstriction, which plays a significant role in temperature
      regulation. Spinal anesthesia also causes redistribution of core heat from the trunk (below
      the block level) to the peripheral tissues. These two effects predispose patients to
      hypothermia and shivering. The median incidence of shivering related to regional anesthesia
      observed in a review of 21 studies is 64.4%. Shivering increases oxygen consumption, lactic
      acidosis, carbon dioxide production, and metabolic rate by up to 400%. Therefore, shivering
      may cause problems in patients with low cardiac and pulmonary reserves. The best way to avoid
      these intraoperative and postoperative shivering-induced increases in hemodynamic and
      metabolic demands is to prevent shivering in the first place. Although magnesium is among
      several pharmacological agents used for the treatment of shivering, its effects on prevention
      of shivering during central neuraxial blockade have not been evaluated to date. Henceforth,
      the aim of this study was to evaluate the effect of magnesiume on shivering during spinal
      anesthesia.

      Aim:

      to compare the efficacy of intravenous versus intrathecal magnesium sulphate for prevention
      of post spinal shivering in adult patients undergoing elective lower limb orthopedic
      surgeries.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 15, 2020</start_date>
  <completion_date type="Anticipated">June 2020</completion_date>
  <primary_completion_date type="Anticipated">June 2020</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>The patients will be randomly allocated to Groups ([T], Intrathecal MgSo4 and [M], IV infusion MgSo4 groups) on the basis of computer-generated random numbers. Patients belonging to Group T (n = 45) will receive 50 mg intrathecal MgSo4 added to 0.5% hyperbaric bupivacaine [131],while those belonging to Group M (group, n = 45) will receive IV magnesium sulfate 50 mg/kg in 100 mL isotonic saline over 20 min as a bolus then 2 mg/kg/h infusion using a separate infusion set after administering spinal anesthesia.
Axillary temperature and grades of shivering will be noted every 10 min by the same anesthesiologist who performed the spinal anesthesia using Crossley and Mahajan scale,[8] If grade III, IV shivering persisted for &gt;10 min pethidine 25 mg IV will be administered as a rescue drug and number of patients required rescue drug will be recorded.</intervention_model_description>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>incidence of postspinal shivering</measure>
    <time_frame>up to 5 months</time_frame>
    <description>the efficacy of the use of MgSo4 IV infusion versus intrathecal injection in decreasing the incidence of postspinal shivering using Crossley and Mahajan scale which is 0, no shivering; 1, piloerection or peripheral vasoconstriction (cyanosis) but no visible shivering; 2, muscular activity in only one muscle group; 3, muscular activity in more than one muscle group but not generalized shivering; and 4, shivering involving the whole body</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">90</enrollment>
  <condition>Prevention of Postspinal Shivering</condition>
  <arm_group>
    <arm_group_label>Intrathecal Mg group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>45 patients will receive 50 mg intrathecal MgSo4 added to 0.5% hyperbaric bupivacaine</description>
  </arm_group>
  <arm_group>
    <arm_group_label>IV Mg infusion group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>45 patients will receive IV magnesium sulfate 50 mg/kg in 100 mL isotonic saline over 20 min as a bolus then 2 mg/kg/h infusion using a separate infusion set after administering spinal anesthesia</description>
  </arm_group>
  <arm_group>
    <arm_group_label>control</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>0.5% heavy bupivacaine in the spinal with no additives</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Magnesium Sulfate 1000 MG</intervention_name>
    <description>intrathecal versus IV infusion of Magnesium sulfate for prevention of postspinal shivering</description>
    <arm_group_label>IV Mg infusion group</arm_group_label>
    <arm_group_label>Intrathecal Mg group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age between 20-45 years old

          -  Both genders

          -  ASA I, II

        Exclusion Criteria:

          -  Patients with hemodynamic instability

          -  cardiopulmonary

          -  renal , liver disease

          -  hypo or hyperthyroidism

          -  cerebrovascular insufficiency

          -  coagulation defects

          -  those with psychiatric disorder

          -  patients receiving vasoactive drugs or beta blockers

          -  BMI &gt; 35

          -  allergic to study drug

          -  height &lt;160 cm or &gt;190 cm

          -  basal body temperature &gt;38°C or &lt;36°C

          -  those who received blood transfusion or &gt;2000 mL fluid intra-operatively

          -  surgery duration &gt; 3 hours
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Sherif Abdullah Mohamed, M.D.</last_name>
    <phone>01002013497</phone>
    <phone_ext>02</phone_ext>
    <email>dr.sherif213@yahoo.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Ayman Mohamed Hossam, M.D.</last_name>
    <phone>01006381196</phone>
    <phone_ext>02</phone_ext>
    <email>aymanhussam@yahoo.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>anesthesia department at Cairo University</name>
      <address>
        <city>Cairo</city>
        <state>Elmanial</state>
        <zip>11562</zip>
        <country>Egypt</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ashraf mohamed Rady, M.D.</last_name>
      <phone>01222224057</phone>
      <phone_ext>02</phone_ext>
      <email>anesthesia.kasralainy@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Sherif Abdullah Mohamed, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ayman mohamed Hossam, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <reference>
    <citation>1. Frank S.M., Higgins M.S., Breslow M.J., et al. The catecholamine, cortisol, and hemodynamic responses to mild perioperative hypothermia: a randomized clinical trial Anesthesiology,1995, 82:83-93. 2. Crowley LJ, Buggy DJ .Shivering and neuraxial anesthesia.Reg Anesth Pain Med. 2008 May-Jun;33(3):241-52. doi: 10.1016/j.rapm.2007.11.006. 3. Mizobe T., Nakajima Y., Sunaguchi M., et al.Clonidine produces a dose-dependant impairment of baroreflex-mediated thermoregulatory responses to positive end-expiratory pressure in anesthetized humans.BJA, 2005, 94:536-541 4. Witte J. De, Sessler D.I.Perioperative shivering: physiology and pharmacology.Anesthesiology, 2002,96:467-484 5. Eberhart LH, Döderlein F, Eisenhardt G, et al Independent risk factors for postoperative shivering. Anesth Analg,2005, 101:1849-1857. 6. Lyons B, Power C, Casey W.Postanaesthesia shivering in children. Anaesthesia 1996.51: 442-445. 7. Hull D, Smales . Heat production in the newborn. In: Sinclair JC (eds.) Temperature Regulation and Energy Metabolism in the Newborn. Grune&amp; Stratton, New York.1978 46:129-156 8. Crossley AW, Mahajan RP. The intensity of postoperative shivering is unrelated to axillary temperature. Anaesthesia 1994,49:205-207 9. P. Kranke, L.H. Eberhart, N. Roewer, M.R. TramerSingle-dose parenteral pharmacological interventions for the prevention of postoperative shivering: a quantitative systematic review of randomized controlled trials Anesth Analg, 2004, 99 :718-727 10. T. Ikeda, T. Kazama, D.I. Sessler, et al.Induction of anesthesia with ketamine reduces the magnitude of redistribution hypothermia.Anesth Analg, 2001,93: 934-938 11. S. Kizilirmak, S.E. Karakas, O. Akca, et al.Magnesium sulfate stops postanesthetic shivering.Ann NY Acad Sci, 1997813: 799-806 12. R.M. Zweifler, M.E. Voorhees, M.A. Mahmood, M. Parnell.Magnesium sulfate increases the rate of hypothermia via surface cooling and improves comfort.Stroke, 2004,35:2331-2334 13. D.B. Cotton, M. Hallak, C. Janusz, S.M. Irtenkauf, R.F. BermanCentral anticonvulsant effects of magnesium sulfate on N-methyl-D-aspartate-induced seizures.Am J Obstet Gynecol, 1993,168:974-978 14. C. Lee, X. Zhang, W.F. Kwan.Electromyographic and mechanomyographic characteristics of neuromuscular block by magnesium sulphate in the pig.Br J Anaesth, 1996,76:278-283 15. V. Rukshin, P.K. Shah, B. Cercek, A. Finkelstein, V. Tsang, S. Kaul.Comparative antithrombotic effects of magnesium sulfate and the platelet glycoprotein IIb/IIIa inhibitors tirofiban and eptifibatide in a canine model of stent thrombosis.Circulation, 2002,105:1970-1975 16. Gozdemir M, Usta B, Demircioglu RI, Muslu B, Sert H, Karatas OF. Magnesium sulfate infusion prevents shivering during transurethral prostatectomy with spinal anesthesia: a randomized, double-blinded, controlled study. J Clin Anesth. 2010,22:184-189.</citation>
  </reference>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>January 28, 2020</study_first_submitted>
  <study_first_submitted_qc>January 30, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">January 31, 2020</study_first_posted>
  <last_update_submitted>June 2, 2020</last_update_submitted>
  <last_update_submitted_qc>June 2, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 4, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Cairo University</investigator_affiliation>
    <investigator_full_name>Sherif Abdullah Mohamed</investigator_full_name>
    <investigator_title>Lecturer of anesthesia</investigator_title>
  </responsible_party>
  <keyword>Magnesium Sulfate - postspinal shivering -intrathecal - infusion</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Magnesium Sulfate</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_time_frame>January to May 2020</ipd_time_frame>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

